Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.


TSXV:CZO - Post by User

Comment by prophetoffactzon Jan 04, 2024 10:04am
50 Views
Post# 35810345

RE:RE:RE:RE:RE:RE:RE:A Mickey Mouse Deal / CoQ10 Deal?

RE:RE:RE:RE:RE:RE:RE:A Mickey Mouse Deal / CoQ10 Deal?"The reason it would achieve a large value even at early stage is that the solution targeted a huge unmet medical need with 28 million patients and no alternative solution its expected to be a multi billion $ drug"

It was acquired by Bellus for peanuts.


BRIEF-Bellus Health and the NEOMED Institute announce agreement for development of treatment for chronic cough


* Bellus Health and the NEOMED Institute announce an exclusive worldwide license agreement for the development of a treatment for chronic cough

* Under terms of agreement, Bellus Health will pay neomed an upfront fee of cad $3.2 million

* Upfront fee consists of CAD $1.7 million in cash and CAD $1.5 million with 5.8 million bellus health common shares

* As per agreement, NEOMED will be entitled to receive a royalty on net sales-based revenues

 

<< Previous
Bullboard Posts
Next >>